NasdaqGS - Nasdaq Real Time Price • USD
Generation Bio Co. (GBIO)
As of 11:41 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 7 |
| Avg. Estimate | -0.31 | -0.28 | -1.68 | -1.05 |
| Low Estimate | -0.52 | -0.4 | -2.35 | -1.57 |
| High Estimate | -0.21 | -0.16 | -0.89 | -0.51 |
| Year Ago EPS | -0.47 | -0.43 | -1.96 | -1.68 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 7 | 5 |
| Avg. Estimate | 1.96M | 2.1M | 7.75M | 7.61M |
| Low Estimate | -- | -- | 4.06M | -- |
| High Estimate | 3.5M | 3.2M | 14.06M | 15.46M |
| Year Ago Sales | 880k | 2.15M | 5.9M | 7.75M |
| Sales Growth (year/est) | 122.70% | -2.10% | 31.30% | -1.80% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.5 | -0.5 | -0.45 | -0.41 |
| EPS Actual | -0.47 | -0.43 | -0.53 | -1.12 |
| Difference | 0.03 | 0.07 | -0.08 | -0.71 |
| Surprise % | 6.00% | 14.00% | -17.80% | -173.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.31 | -0.28 | -1.68 | -1.05 |
| 7 Days Ago | -0.38 | -0.35 | -1.49 | -1.3 |
| 30 Days Ago | -0.38 | -0.35 | -1.49 | -1.3 |
| 60 Days Ago | -0.39 | -0.36 | -1.54 | -1.32 |
| 90 Days Ago | -0.43 | -0.41 | -1.68 | -1.35 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | 5 |
| Up Last 30 Days | 5 | 5 | 1 | 5 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | 4 | -- |
Growth Estimates
| CURRENCY IN USD | GBIO | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 34.00% | -- | -- | 8.00% |
| Next Qtr. | 34.90% | -- | -- | 12.40% |
| Current Year | 14.30% | -- | -- | 5.60% |
| Next Year | 37.50% | -- | -- | 12.60% |
| Next 5 Years (per annum) | -- | -- | -- | 11.14% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Needham: Buy to Buy | 5/14/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 5/14/2024 |
| Reiterates | Needham: Buy to Buy | 4/10/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 3/7/2024 |
| Maintains | Needham: Buy to Buy | 3/7/2024 |
| Maintains | Wedbush: Outperform to Outperform | 11/10/2023 |
Related Tickers
BCAB BioAtla, Inc.
2.7250
-3.73%
QTTB Q32 Bio Inc.
30.21
-0.49%
ANNX Annexon, Inc.
4.4700
+3.23%
CGEM Cullinan Therapeutics, Inc.
23.64
+2.03%
ALGS Aligos Therapeutics, Inc.
0.6701
-2.67%
AVTE Aerovate Therapeutics, Inc.
20.58
+0.02%
TSHA Taysha Gene Therapies, Inc.
3.1450
+1.78%
IKNA Ikena Oncology, Inc.
1.4400
+0.70%
AUTL Autolus Therapeutics plc
4.2250
-3.76%
NKTX Nkarta, Inc.
6.74
+3.22%